Skip to content

DiNovA Israel

DiNovA Israel is a medtech incubator based in Caesarea, Israel, focused on fostering digital health innovations by connecting Israeli engineering talent with the Chinese healthcare market. It aims to support early-stage medtech companies through funding and infrastructure.

Founded
2020

Online destinations

Find DiNovA Israel online

Public destinations are grouped by their documented relationship to the organization. A listed link does not by itself prove ownership or control.

Official links

Destinations the organization presents as part of its public presence.

Overview

DiNovA Israel was founded in April 2020 as a medtech incubator to promote cutting-edge technologies, particularly in digital health. The organization connects Israeli engineering talent with the Chinese healthcare market, providing resources for product development and commercialization. DiNovA Israel is part of DiNovA Medtech, a China-headquartered incubator established in 2009. The incubator focuses on early-stage projects in medtech, digital health, and related fields, offering support through funding and infrastructure. Despite its promising mission, recent independent research indicates that DiNovA Israel may be inactive, with no verified public activity since 2021.

Superscout Pro

Build a scout record investors can understand.

  • Keep a private deal vault with timestamps
  • Write richer memos and evaluations
  • Compare investor and program fit
  • Manage sources, next actions, and follow-up
$99$249 first year
Superscout Pro
Illustrative
Illustrative scout
Scout profile Structured activity
Memo drafted
Submitted
Following

Superscout documents DiNovA Israel independently from canonical records and linked sources. Missing facts stay missing.

Sources and known limits

A reviewed date is not available for this page.

Terms, dates, and eligibility can change. Confirm time-sensitive details with the original source.

Superscout is not affiliated with, endorsed by, or acting on behalf of the organizations documented here.